El Dr. Luis Paz-Ares, investigador del Instituto i+12, ha participado en el desarrollo de este nuevo tratamiento oncológico, el cual representa una nueva terapia disponible en una patología de especial mal pronóstico.
Fuente: El Mundo.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
You can also learn more about our Cookie policy and Data protection policy.